Monoclonal antibody A717

Drug Profile

Monoclonal antibody A717

Alternative Names: A 717; HuA717; HuA717 scFv

Latest Information Update: 08 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exocell
  • Developer Glycadia
  • Class Monoclonal antibodies
  • Mechanism of Action Glycosylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic complications

Most Recent Events

  • 08 May 2003 No development reported - Preclinical for Diabetic complications in USA (unspecified route)
  • 22 Jul 1996 Exocell has a US patent to develop monoclonal antibody A717 for kidney disease and other complications of diabetes
  • 22 Jul 1996 Preclinical development for Diabetic complications in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top